Medical

According to researchers from the Duke Clinical Research Institute (DCRI) and Vanderbilt University, the ACTIV-6 study of repurposed medicines for the treatment of mild-to-moderate COVID-19 has found that inhaled dry powder fluticasone furoate provided no benefit compared to inhaled placebo. Results have been published on medRxiv in an article titled "Inhaled … [Read more...] about Study finds fluticasone furoate DPI ineffective for the treatment of COVID-19

Odyssey Health said that a Phase 1 single ascending dose trial of PRV-002 nasal spray, which it describes as "a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of mTBI (concussion)," has been completed. According to Odyssey, the trial found a linear dose response, and all dose levels were safe and well tolerated. In addition to … [Read more...] about Odyssey Health says PRV-002 nasal spray safe and well tolerated in Phase 1 SAD trial

Glenmark Pharmaceuticals and SaNOtize have announced the publication of results from a Phase 3 clinical trial of NONS nitric oxide nasal spray for the treatment of COVID-19 in The Lancet Regional Health Southeast Asia. SaNOtize announced initiation of the Phase 3 trial in June 2021, and Glenmark announced in August 2021 that it had acquired the rights to NONS in India … [Read more...] about Glenmark and SaNOtize publish positive results from Phase 3 trial of nitric oxide nasal spray for COVID-19

Pulmatrix said that the first subjects have been dosed in a Phase 1 trial of the company's PUR3100 dry powder dihydroergotamine (DHE), which is based on Pulmatrix's iSPERSE particle engineering platform. The company announced in March 2021 that it intended to develop the PUR3100 DPI for the treatment of migraines. The Phase 1 trial is expected to enroll 24 healthy … [Read more...] about Pulmatrix initiates Phase 1 trial of PUR3100 inhaled dry powder DHE

US-based startup RS BioTherapeutics has announced that a proof of concept study demonstrated that its RSBT-001 semi-synthetic cannabidiolic acid (CBDa) reduced but did not eliminate cytokines when dosed intranasally at 1 mg/kg in a mouse model of pulmonary inflammation. The study was conducted by researchers at Marshall University. RS BioTherapeutics licensed the … [Read more...] about RS BioTherapeutics reports positive preclinical results for its inhaled CBDa

Danish startup Cessatech, a spin out from Rigshospitalet, announced that it has gotten the go-ahead for a pivotal trial of its CT001 analgesic nasal spray. Cessatech is developing CT001, a fixed dose combination of sufentanil and ketamine, for use in pediatric patients and has already completed dosing in a Phase 2 PK study of the nasal spray in children aged 1-17. … [Read more...] about Cessatech announces plans for pivotal trial of CT001 intranasal analgesic

Orexo announced the initiation of a Phase 1 trial of its OX640 intranasal dry powder adrenaline, which the company is developing for emergency treatment of anaphylaxis. The OX640-001 study will compare several formulations of OX640 to intramuscular adrenaline in healthy volunteers. OX640 is based on Orexo's amorphOX particle engineering technology, which is also … [Read more...] about Orexo initiates Phase 1 trial of OX640 intranasal dry powder adrenaline

Receptor Life Sciences said that a Phase 1b/2a trial of its RLS103 cannabidiol DPI in social anxiety disorder patients with acute anxiety has gotten underway. The trial is expected to enroll approximately 30 patients who will get either 3 mg of RLS103, 6 mg of RLS103, or an inhaled dry powder placebo prior to a public speaking challenge. The RLS103 formulation … [Read more...] about Receptor initiates Phase 1b/2a trial of RLS103 dry powder CBD in patients with SAD

FluGen said that the first subject has been dosed in a Phase 1b study of its M2SR intranasal live single replication flu vaccine and an intramuscular high dose inactivated vaccine (IIV) in adults aged 65 to 85 years. The study, which is funded by the US Department of Defense, will evaluate each of the vaccines separately, as well as the intranasal and IIV vaccines … [Read more...] about Phase 1b study of FluGen’s intranasal flu vaccine in older adults gets underway